Erika Hamilton, MD, Sarah Cannon Research Institute, Nashville, TN, discusses the results of the MARIO-3 (NCT03961698), a Phase II study in triple-negative breast cancer (TNBC) evaluating eganelisib, a first-in-class, oral PI3K-gamma inhibitor in combination with nab-paclitaxel and atezolizumab. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).